BioNanomatrix CEO Michael Boyce-Jacino told GenomeWeb News that the NCI grant is a two-year, $240,000 SBIR Phase I grant for development of a cancer diagnostic prototype.
Boyce-Jacino added that 21 Ventures will provide bridge financing to help support the company until its expected Series A financing closes later this year, while Ben Franklin Technology Partners of Southeastern Pennsylvania has made a seed investment in the company.
He declined to provide more information on how much 21 Ventures and Ben Franklin Partners have invested in BioNanomatrix.